JPWO2020227177A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227177A5 JPWO2020227177A5 JP2021564704A JP2021564704A JPWO2020227177A5 JP WO2020227177 A5 JPWO2020227177 A5 JP WO2020227177A5 JP 2021564704 A JP2021564704 A JP 2021564704A JP 2021564704 A JP2021564704 A JP 2021564704A JP WO2020227177 A5 JPWO2020227177 A5 JP WO2020227177A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- grade
- administered
- steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010052015 cytokine release syndrome Diseases 0.000 claims 7
- 150000003431 steroids Chemical class 0.000 claims 7
- 206010029350 Neurotoxicity Diseases 0.000 claims 6
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 6
- 231100000228 neurotoxicity Toxicity 0.000 claims 6
- 230000007135 neurotoxicity Effects 0.000 claims 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 238000009121 systemic therapy Methods 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 206010067484 Adverse reaction Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 230000006838 adverse reaction Effects 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025013168A JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843190P | 2019-05-03 | 2019-05-03 | |
| US62/843,190 | 2019-05-03 | ||
| US201962855828P | 2019-05-31 | 2019-05-31 | |
| US62/855,828 | 2019-05-31 | ||
| US201962868262P | 2019-06-28 | 2019-06-28 | |
| US62/868,262 | 2019-06-28 | ||
| US201962931669P | 2019-11-06 | 2019-11-06 | |
| US62/931,669 | 2019-11-06 | ||
| US201962944903P | 2019-12-06 | 2019-12-06 | |
| US62/944,903 | 2019-12-06 | ||
| PCT/US2020/031231 WO2020227177A1 (en) | 2019-05-03 | 2020-05-03 | Methods of administering chimeric antigen receptor immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Division JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532865A JP2022532865A (ja) | 2022-07-20 |
| JP2022532865A5 JP2022532865A5 (https=) | 2023-05-15 |
| JPWO2020227177A5 true JPWO2020227177A5 (https=) | 2023-05-15 |
Family
ID=73050885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564704A Pending JP2022532865A (ja) | 2019-05-03 | 2020-05-03 | キメラ抗原受容体免疫療法の投与方法 |
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200384027A1 (https=) |
| EP (2) | EP4249075A3 (https=) |
| JP (2) | JP2022532865A (https=) |
| KR (1) | KR20220005075A (https=) |
| CN (3) | CN118662516A (https=) |
| AU (2) | AU2020267378B2 (https=) |
| BR (1) | BR112021021996A2 (https=) |
| CA (1) | CA3138707A1 (https=) |
| IL (1) | IL287533A (https=) |
| MX (1) | MX2021013394A (https=) |
| SG (1) | SG11202112123RA (https=) |
| TW (1) | TW202108150A (https=) |
| WO (1) | WO2020227177A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200384027A1 (en) * | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| US20220184208A1 (en) * | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2022137186A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| CN113406334A (zh) * | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | 一种dlbcl相关的生物标记组合物及其应用、dlbcl预后的效果预测模型 |
| US20230268031A1 (en) * | 2021-07-30 | 2023-08-24 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
| CN113786490A (zh) * | 2021-09-14 | 2021-12-14 | 华中科技大学同济医学院附属协和医院 | 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| NZ609201A (en) * | 2010-10-27 | 2015-01-30 | Amgen Res Munich Gmbh | Means and methods for treating dlbcl |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| JP2017505819A (ja) | 2014-02-04 | 2017-02-23 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物 |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| EP3364969A4 (en) | 2015-10-20 | 2019-07-10 | Kite Pharma, Inc. | METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US20190336504A1 (en) * | 2016-07-15 | 2019-11-07 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| SG10201912400VA (en) * | 2017-04-24 | 2020-02-27 | Kite Pharma Inc | Humanized antigen-binding domains against cd19 and methods of use |
| AU2018275894B2 (en) * | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| EP3691663A4 (en) * | 2017-10-02 | 2021-08-18 | Humanigen, Inc. | METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST |
| CA3084470A1 (en) * | 2017-10-18 | 2019-04-25 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| US20200384027A1 (en) * | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
-
2020
- 2020-05-03 US US16/865,369 patent/US20200384027A1/en not_active Abandoned
- 2020-05-03 SG SG11202112123RA patent/SG11202112123RA/en unknown
- 2020-05-03 CN CN202410645821.4A patent/CN118662516A/zh active Pending
- 2020-05-03 CN CN202410645866.1A patent/CN118593691A/zh active Pending
- 2020-05-03 BR BR112021021996A patent/BR112021021996A2/pt unknown
- 2020-05-03 CN CN202080043985.XA patent/CN114206346A/zh active Pending
- 2020-05-03 KR KR1020217039585A patent/KR20220005075A/ko not_active Ceased
- 2020-05-03 MX MX2021013394A patent/MX2021013394A/es unknown
- 2020-05-03 EP EP23186520.5A patent/EP4249075A3/en active Pending
- 2020-05-03 EP EP20801592.5A patent/EP3962490A4/en not_active Withdrawn
- 2020-05-03 AU AU2020267378A patent/AU2020267378B2/en active Active
- 2020-05-03 CA CA3138707A patent/CA3138707A1/en active Pending
- 2020-05-03 JP JP2021564704A patent/JP2022532865A/ja active Pending
- 2020-05-03 TW TW109114736A patent/TW202108150A/zh unknown
- 2020-05-03 WO PCT/US2020/031231 patent/WO2020227177A1/en not_active Ceased
-
2021
- 2021-10-24 IL IL287533A patent/IL287533A/en unknown
-
2023
- 2023-02-10 US US18/167,725 patent/US20230270785A1/en active Pending
-
2025
- 2025-01-29 JP JP2025013168A patent/JP2025069275A/ja active Pending
- 2025-04-30 AU AU2025203054A patent/AU2025203054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156736A5 (https=) | ||
| Lancman et al. | Bispecific antibodies in multiple myeloma: present and future | |
| Brudno et al. | Chimeric antigen receptor T-cell therapies for lymphoma | |
| Guo et al. | Phase I study of chimeric antigen receptor–modified T cells in patients with EGFR-positive advanced biliary tract cancers | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Wu et al. | CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma | |
| Jia et al. | Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation | |
| Tsai et al. | A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies | |
| Paul et al. | Treatment of relapsed/refractory acute lymphoblastic leukemia | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| JP2021509009A5 (https=) | ||
| JP2020519600A5 (https=) | ||
| Burton et al. | Bispecific antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efficacy from toxicity | |
| KR20240145059A (ko) | 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도 | |
| JP2018522851A5 (https=) | ||
| JPWO2020227177A5 (https=) | ||
| Cao et al. | Small-molecule compounds boost CAR-T cell therapy in hematological malignancies | |
| Guo et al. | Effective antitumor activity of 5T4‐specific CAR‐T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo | |
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| JP2017537927A5 (https=) | ||
| Guo et al. | Targeting BCMA to treat multiple myeloma: updates from the 2021 ASH annual meeting | |
| Nastoupil et al. | CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received≥ 1 line of systemic therapy | |
| Zhang et al. | Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma | |
| Miklos et al. | Leveraging the immunomodulatory potential of Ibrutinib for improved outcomes of T cell-mediated therapies of B cell malignancies: a narrative review |